Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Mural Oncology PLC (MURA : NSDQ)

• Company Description    Mural Oncology plc is a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Mural Oncology plc is based in DUBLIN, Ireland. Number of Employees: 116

• Price / Volume Information    Yesterday's Closing Price: $2.08 Daily Weekly Monthly 20 Day Moving Average: 463,506 shares Shares Outstanding: 17.32 (millions) Market Capitalization: $36.03 (millions) Beta: 2.99 52 Week High: $4.74 52 Week Low: $0.95 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 17.51% 15.45% 12 Week -15.79% -23.51% Year To Date -35.40% -42.60%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10 Earlsfort Terrace - Dublin,L2 D02 T380 IRL ph: 353-1905-8020 fax: - ir@muraloncology.com http://www.muraloncology.com

• General Corporate Information    Officers Caroline Loew - Chief Executive Officer and Director Scott Jackson - Chairman of the Board of Directors Adam Cutler - Chief Financial Officer Francis Cuss - Director George Golumbeski - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: G63365103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/12/25 Share - Related Items Shares Outstanding: 17.32 Most Recent Split Date: (:1) Beta: 2.99 Market Capitalization: $36.03 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.59 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-5.66 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.61 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 4.84% vs. Previous Quarter: 8.29% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -107.76 03/31/25 - -83.39 12/31/24 - -68.16 ROA 06/30/25 - -87.57 03/31/25 - -70.70 12/31/24 - -59.01 Current Ratio 06/30/25 - 2.87 03/31/25 - 5.08 12/31/24 - 5.84 Quick Ratio 06/30/25 - 2.87 03/31/25 - 5.08 12/31/24 - 5.84 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 3.39 03/31/25 - 6.25 12/31/24 - 8.22 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©